The U.S. Food and Drug Administration (FDA) has approved a new treatment regimen that includes Pfizer’s ADCETRIS® (brentuximab vedotin) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This is an important development as it provides a new option for individuals who have not responded to at least two previous therapies and are not candidates for more aggressive treatments such as stem cell transplantation or CAR T-cell therapy.
The US FDA has approved a new expanded label for Astellas Pharma’s IZERVAY™ (avacincaptad pegol intravitreal solution) to treat geographic atrophy (GA) due to age-related macular degeneration (AMD) long-term. The expansion provides physicians and patients with more options for treating this progressive and chronic eye disease, which can cause irreversible vision loss.
A new study, reported at the International Stroke Conference, indicates that a medication called liraglutide, which is often used for diabetes under the brand names Victoza and Saxenda, can benefit patients who’ve had mini-strokes or transient ischemic attacks (TIAs) and have diabetes.
The study, titled “The protective effect of sodium-glucose cotransporter-2 inhibitor on left ventricular global longitudinal strain in patients with type 2 diabetes mellitus according to disease duration,” investigates the impact of SGLT2 inhibitors on heart function in type 2 diabetes patients.
The study investigated the effects of canagliflozin (CANA), a sodium-glucose transporter-2 inhibitor (SGLT2i), on bone health using genetically heterogeneous UM-HET3 mice. CANA is typically used to lower blood glucose levels independently of insulin but also induces various metabolic changes, including weight loss and impaired bone integrity. The research aimed to understand how CANA affects bone metabolism, given that SGLT2 is not expressed in osteoblasts or osteocytes, which are crucial for bone remodeling.
